Inclusion Criteria:

          -  Aged at least 18 years

          -  Provision of signed and dated, written informed consent.

          -  Histological or cytological confirmation of locally advanced, unresectable or
             metastatic solid malignancy.

          -  Performance status: Eastern Co-operative Oncology Group (ECOG) ≤1 and life expectancy
             ≥3 months.

          -  Ability to swallow and retain oral medication.

          -  Adequate organ functions.

          -  Females of child-bearing potential:

               -  Must use a highly effective method contraceptive measures during the study and
                  for 1 month after the last dose of OMO 1.

               -  Must not be breast feeding.

               -  Must have a negative pregnancy test prior to start of dosing.

          -  Sexually active male patients must be willing to use barrier contraception

        Exclusion Criteria:

          -  Patients receiving other cancer therapy, or other investigational product apart from
             the combination agent(s) described in the relevant combination modules.

          -  Patients who have received radiotherapy for the primary tumour within 1 week from the
             screening visit.

          -  Patients receiving medications predominantly metabolized by CYP2B6.

          -  Patients receiving cannabinoid substances.

          -  Patients receiving St John's Wort.

          -  Patients receiving medications that are known to have potent aldehyde oxidase (AO)
             inhibitory activity.

          -  Patients with prior splenectomy.

          -  Patients testing positive for human immunodeficiency virus (HIV) infection, hepatitis
             B based on findings of persistent hepatitis B virus surface antigen (HBsAg) or other
             serology test, hepatitis C virus (HCV) or Epstein-Barr Virus (EBV) infection.

          -  Patients with current, or a history of uveitis.

          -  Patients with any known uncontrolled inter-current illness including ongoing or active
             infections, symptomatic congestive heart failure, conditions that could adversely be
             affected by hypertension or tachycardia, unstable angina pectoris, cardiac arrhythmia,
             or psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Patients with a history or clinical evidence of neoplastic central nervous system
             (CNS) involvement if not stable for 9 weeks prior to the first dose of study
             treatment.

          -  Patients with major and/or planned surgery within 12 weeks of the first dose of study
             treatment.

          -  Patients with any known severe allergies (e.g., anaphylaxis) to any active or inactive
             ingredients in OMO-1.

          -  Patients with nephrolithiasis.

          -  Patients with current, or a history of any seizure or seizure disorder. This includes
             receiving, or having received, seizure threshold-raising medication for the treatment
             of epilepsy.

        In addition to the main core eligibility criteria, Module specific eligibility criteria
        include:

        Module 1:

        Patient recruited into the paired biopsy cohorts of Part A must have:

          -  at least 1 lesion suitable for biopsy.

          -  tumours that are MET gene amplified and/or mutated.

          -  had no prior therapy with a selective MET inhibitor.

        Patients recruited into Part B cohorts must have:

          -  tumours that are MET gene amplified and/or mutated.

          -  at least one lesion, not previously irradiated, that can be accurately measured at
             baseline.

          -  had no prior therapy with a selective MET inhibitor.

          -  no coinciding malignancy that would impact on survival.

          -  no metastasis limited to the bone only.

        Module 2:

        Patients recruited into Part A and Part B cohorts must have:

          -  tumours that are EGFR gene mutant that are currently progressing on treatment with a
             small molecule EGFR-TKI. Enrolment must be restricted to patients that are resistant
             to all relevant EGFR TKI therapy according to their tumour mutated status.

          -  received the EGFR-TKI as monotherapy for at least 12 weeks.

          -  tolerated their current dose of EGFR-TKI for at least 12 weeks.

          -  tumours that are MET gene amplified.

          -  had no prior therapy with a selective MET inhibitor.

          -  had no prior EGFR-TKI treatment of >2 lines.

          -  no past medical history of ILD, drug-induced ILD, radiation pneumonitis which required
             steroid treatment, or any evidence of clinically active ILD.

          -  no significant GI disorders with diarrhoea as a major symptom e.g., Crohn's disease,
             mal-absorption, or CTCAE Grade >1 diarrhoea of any aetiology at the enrolment.

          -  no contra-indications (as per the relevant medication package insert) for therapy with
             the EGFR-TKI routinely used by their oncology unit.

        In addition, patients recruited into Module 2 Part B cohorts must have:

          -  at least one lesion, not previously irradiated, that can be accurately measured at
             baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short
             axis ≥15 mm) with CT or MRI and which is suitable for accurate repeated assessment.

          -  no coinciding malignancy that would impact on survival.

          -  no metastasis limited to the bone only.